Episode Summary
In this first part of a special two-episode series of TOGA’s Conversations in Lung Cancer Research podcast, A/Prof Deme Karikios, a Medical Oncologist at the Nepean Hospital in NSW, is joined by Prof Ken O’Byrne, a Consultant and Professor in Medical Oncology at the Princess Alexandra Hospital and the Queensland University of Technology, and A/Prof Rachel Roberts-Thomson, a Medical Oncologist at The Queen Elizabeth Hospital and Cancer Care Adelaide.
The panel discusses the recent, groundbreaking broad PBS listing of certain immunotherapy agents in Australia, including the removal of ‘once in a life time’ rule. This major structural shift moves oncology prescribing away from rigid, indication-specific silos and toward clinician discretion guided by a patient’s individual biology and the best available clinical evidence. This episode also covers what this means for advanced and metastatic thoracic malignancies, the biological rationale behind single versus doublet immunotherapy, and the practicalities of managing these clinical decisions.
Sponsors
This podcast was proudly sponsored by Bristol Myers Squibb. All development and editorial decisions were made independently by the speakers.
Speakers
- A/Prof Deme Karikios, Medical Oncologist, Nepean Hospital
- Prof Ken O’Byrne, Consultant and Professor in Medical Oncology, Princess Alexandra Hospital and the Queensland University of Technology
- A/Prof Rachel Roberts-Thomson, Medical Oncologist, The Queen Elizabeth Hospital and Cancer Care Adelaide
